Study on efficacy and safety of Hochuekkito for the treatment of partial paralysis as a complication of cerebrovascular disorder

Study on efficacy and safety of Hochuekkito for the treatment of partial paralysis as a complication of cerebrovascular disorder - Efficacy of Hochuekkito for "partial paralysis" in patients undergoing rehabilitation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021801

Enrollment

100

Registered

2016-04-06

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing rehabilitation for partial paralysis as a complication of cerebrovascular disorder

Interventions

TSUMURA Hochuekkito Extract Granules for Ethical Use control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with partial paralysis as a complication of cerebrovascular disorder 2)Patients with Functional Independence Measur(FIM;foe ADL evaluation) score of 40 points or lower 3)Recovering patients who have started rehabilitation within 1 week 4)Patients with Alb of less than 3.5g/dL 5)Patients aged 50 years or older and younger than 80 years (when giving informed consent) 6)Patients who can take oral investigational drugs 7)Both males and females are eligible 8)Inpatients 9)Patients who are able to give written informed consent

Exclusion criteria

Exclusion criteria: Patients who have any of the following conditions: 1)Insufficient nutrition intake (less than 1,400kcal/day) 2)CRP of 10g/dL or more 3)Grade 2 or severer on the physical disability certificate or Grade 3 or severer certification of long-term care need since before the onset of cerebrovascular disorder 4)Use of any Kampo medicine within 4 weeks before study initiation 5)Serious comorbidities (e.g., hepatic, renal, cardiac, hematological, and metabolic diseases) 6)Any other condition assessed as inappropriate for study participation by the investigator or subinvestigator (hereinafter referred to as "investigators, etc.")

Design outcomes

Primary

Measure	Time frame
FIM(Functional Independence Measure)	—

Secondary

Measure	Time frame
Alb,Body weight,BMI,%Ideal body weight,Lymphocyte number,Hb,CRP,Incidence rate of complication	—

Countries

Japan

Contacts

Public ContactNaoki Fukumura

Tsuruoka Kyoritu Rehabilitation Hospital Department of Rehabilitation

fukumuranaoki@gmail.com0235-78-7511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026